Skip to content
Peptides Networkby Compounded Health
Menu

Article

Thymosin Alpha-1: Why the Largest Sepsis Trial Changed the Evidence

Smaller studies suggested lower death rates in sepsis; a placebo-controlled trial of 1,106 adults did not confirm it

3 min read Evidence checked October 18, 2026 Key takeaways 8 sources

In this article

Key takeaways

Thymosin alpha-1 is a 28-amino-acid peptide studied in hepatitis, cancer and sepsis. In the largest placebo-controlled sepsis trial (TESTS, 1,106 adults), it did not lower 28-day mortality; the evidence for other uses comes from small, older trials. It is not FDA-approved.

Evidence available
Randomized trials in people
Confidence
Moderate For sepsis mortality, one large double-blind trial with a null result outweighs earlier small and partly unmasked trials; evidence for other uses is limited.
Main limitation
TESTS was run in China, and its confidence interval does not rule out a modest benefit; the hepatitis and cancer evidence comes from small trials summarized in reviews.
Evidence checked See all 8 sources
AI-generated illustration: translucent round cells drifting in dark fluid, one releasing small glowing violet particles. Conceptual artwork.
AI-generated illustration · conceptual artwork

U.S. regulatory status

  • Thymosin alpha-1

    Not FDA-approved

    Not the active ingredient of any FDA-approved drug (Drugs@FDA search, 2026-10-18). FDA lists thymosin alpha-1 among bulk drug substances that may present significant safety risks in compounding.

    Source 8, verified

Thymosin alpha-1 is a 28-amino-acid peptide, made synthetically under the name Zadaxin, that has been studied as a way to strengthen immune responses in hepatitis, cancer and sepsis 1,4,5. The largest placebo-controlled trial of it in sepsis did not find a benefit. In TESTS, which enrolled 1,106 adults with sepsis and was published in 2025, 28-day mortality was 23.4 percent with thymosin alpha-1 and 24.1 percent with placebo, and the authors found no clear evidence that it lowers death from any cause 5. Earlier, smaller studies that suggested lower mortality carry less weight after that result. Thymosin alpha-1 is not an FDA-approved drug in the United States.

Sepsis: what the trials found

ETASS (2013). In six hospitals in China, 361 adults with severe sepsis were randomized to conventional treatment with or without thymosin alpha-1 in a single-blind design 7. Mortality from any cause within 28 days was 26.0 percent with thymosin alpha-1 and 35.0 percent in the control group. The relative risk was 0.74, with a 95 percent confidence interval of 0.54 to 1.02, which includes no effect 7.

Meta-analysis (2015). A review that pooled 12 controlled trials with 1,480 patients found lower all-cause mortality with thymosin alpha-1-based treatment (risk ratio 0.68; 95% CI 0.59 to 0.78), but its authors warned that the included trials were few, small and of poor quality 3.

TESTS (2025). At 22 centers in China, 1,106 adults aged 18 to 85 with sepsis were randomized to thymosin alpha-1 or placebo in a double-blind design 5. Among the 1,089 analyzed, 28-day all-cause mortality was 23.4 percent with thymosin alpha-1 and 24.1 percent with placebo (hazard ratio 0.99; 95% CI 0.77 to 1.27) 5. No secondary or safety outcome differed significantly between the groups 5. Prespecified subgroup analyses showed what the authors call a potential differential effect by age and by diabetes; in people younger than 60, the estimate pointed toward higher mortality with thymosin alpha-1 (hazard ratio 1.67; 95% CI 1.04 to 2.67) 5. The trial was funded in part by SciClone Pharmaceuticals, which the authors state was not involved in its design, data collection or interpretation 5.

The TESTS authors give several possible reasons for the gap between their result and earlier studies. The earlier studies were small, so their positive results may have been chance findings, and some lacked masking or had imbalanced groups 5. TESTS enrolled nearly twice as many patients as the previous ten trials combined, but its confidence interval still leaves room for a modest reduction in mortality 5. The earlier version of this page named TESTS without reporting its result.

Hepatitis B and C

Thymosin alpha-1 was first studied mainly in chronic viral hepatitis. A 1999 review described it as effective in chronic hepatitis B, alone or with interferon-alpha, and in chronic hepatitis C when combined with interferon-alpha 1. A 2001 review of the trials was more cautious. It counted 195 hepatitis B patients in four trials and 162 hepatitis C patients in three; in one hepatitis C trial, thymosin alpha-1 did no better than placebo at normalizing liver enzyme levels. The review called the results mixed and said effects on illness and death remained to be seen 6.

Cancer

A 2000 review by researchers in Rome described experimental and human studies in which thymosin alpha-1, combined with low-dose interferon or interleukin-2 and with chemotherapy, restored immune responses and increased anti-tumor effects 4. No large randomized cancer trial was checked for this page, and no cancer use of thymosin alpha-1 is FDA-approved.

Safety

In TESTS, no safety outcome differed significantly between the thymosin alpha-1 and placebo groups 5. The 2001 review reported that most studies observed only local irritation where it was injected 6. A 2024 review covering more than 11,000 people in over 30 trials concluded that thymosin alpha-1 is well tolerated, and recommended that FDA allow pharmacies to compound it 2. That review argues for a regulatory position, and it does not replace safety data from large controlled trials such as TESTS.

Status in the United States

Thymosin alpha-1 is not the active ingredient of any FDA-approved drug (Drugs@FDA search, October 18, 2026). FDA lists it among bulk drug substances for compounding that may present significant safety risks: the agency says compounded thymosin alpha-1 may pose a significant risk of immune reactions for certain routes of administration and that the safety information is inadequate. The nomination that had placed it in that category was later withdrawn 8. Approval by regulators in other countries is not FDA approval.

Topics

  • thymosin alpha-1
  • sepsis
  • hepatitis
  • immune system
  • clinical trials

Sources

8 sources. Numbers in the text link to the entry they cite.

  1. 1.
    Zadaxin (thymosin alpha1) for the treatment of viral hepatitis

    Naylor PH. Expert Opin Investig Drugs. 1999.

    Review PMID 15992078 DOI 10.1517/13543784.8.3.281Checked October 18, 2026

    Cited for: Zadaxin is a synthetic 28 amino acid peptide; effective in chronic hepatitis B alone or with IFN-alpha, and in hepatitis C with IFN-alpha

    Back to text (a)Back to text (b)

  2. 2.
    Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials

    Dinetz E, Lee E. Altern Ther Health Med. 2024.

    Systematic review PMID 38308608Checked October 18, 2026

    Cited for: Over 11,000 subjects in more than 30 trials; concludes well tolerated; recommends FDA permit 503A compounding

    Back to text

  3. 3.
    Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis

    Li C, Bo L, Liu Q, Jin F. Int J Infect Dis. 2015.

    Meta-analysis PMID 25532482 DOI 10.1016/j.ijid.2014.12.032Checked October 18, 2026

    Cited for: 12 controlled trials, n=1,480; pooled RR 0.68 (0.59-0.78) for all-cause mortality; poor quality and small trials

    Back to text

  4. 4.
    Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application

    Garaci E, Pica F, Rasi G, Favalli C. Int J Immunopharmacol. 2000.

    Review PMID 11137613 DOI 10.1016/s0192-0561(00)00075-8Checked October 18, 2026

    Cited for: Combinations with low-dose IFN or IL-2 and chemotherapy restored immune responses and increased anti-tumor effect in experimental and human cancers

    Back to text (a)Back to text (b)

  5. 5.
    The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial

    Wu J, Pei F, Zhou L, et al. BMJ. 2025.

    Randomized controlled trial PMID 39814420 DOI 10.1136/bmj-2024-082583Checked October 18, 2026

    Cited for: 22 centres in China; 1,106 adults 18-85 with sepsis; 1,089 analyzed; 28-day mortality 23.4% vs 24.1% (HR 0.99, 0.77-1.27); no clear evidence of reduced mortality; no secondary or safety outcome differed; subgroups by age (<60: HR 1.67, 1.04-2.67) and diabetes; funded in part by SciClone; earlier trials small and partly unmasked; nearly twice the size of the previous 10 trials combined

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)Back to text (h)Back to text (i)Back to text (j)

  6. 6.
    Thymosin alpha-1

    Ancell CD, Phipps J, Young L. Am J Health Syst Pharm. 2001.

    Review PMID 11381492 DOI 10.1093/ajhp/58.10.886Checked October 18, 2026

    Cited for: Hepatitis B: 195 patients in four trials; hepatitis C: 162 patients in three trials, one with no difference from placebo in ALT normalization; mixed results; effects on morbidity and mortality remain to be seen; mostly local injection-site irritation

    Back to text (a)Back to text (b)

  7. 7.
    The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

    Wu J, Zhou L, Liu J, et al. Crit Care. 2013.

    Randomized controlled trial PMID 23327199 DOI 10.1186/cc11932Checked October 18, 2026

    Cited for: Six hospitals in China; 361 patients; 28-day mortality 26.0% vs 35.0%; RR 0.74 (0.54-1.02); nonstratified P=0.062

    Back to text (a)Back to text (b)

  8. 8.
    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026)

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: Thymosin-alpha 1 (Ta1) listed among substances previously in category 2 whose nominations were withdrawn; may pose significant risk for immunogenicity; safety-related information inadequate

    Back to text

Next read

Follow Compounded Health InstagramFacebook

Back to Peptides Network Back to top